GlassScriptPhysician profile
Kostas N Botsoglou
NPI 1295981652
$2,642,964.59
in general payments reported to CMS, 2019-2025
44 companies · $519K in 2025
The $519K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347K · 2020: $230K · 2021: $288K · 2022: $376K · 2023: $408K · 2024: $475K · 2025: $519K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.0M · Travel and Lodging: $217K · Consulting Fee: $83K · Food and Beverage: $53K · Honoraria: $45K · Education: $348 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,003,831.50 |
| Travel and Lodging | $216,934.96 |
| Consulting Fee | $83,120.00 |
| Food and Beverage | $52,772.27 |
| Honoraria | $45,112.50 |
| Education | $348.35 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $664,044.36 | 2020-2025 | Acthar |
| Abbvie INC. | $560,787.79 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $307,117.58 | 2019-2025 | Otezla, Tavneos, Otezla |
| Janssen Biotech, INC. | $164,329.38 | 2019-2025 | Simponi Aria, Tremfya, Stelara |
| Ucb, INC. | $163,061.97 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $151,988.01 | 2019-2025 | Saphnelo |
| Genzyme Corporation | $144,319.35 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $72,880.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $69,602.44 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $67,422.22 | 2022-2025 | Purified Cortrophin Gel |
| Celgene Corporation | $65,652.48 | 2019 | |
| Janssen Scientific Affairs, LLC | $50,427.11 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Kyowa Kirin, INC. | $33,249.46 | 2023-2025 | Crysvita |
| Aurinia Pharma U.S., INC. | $31,669.82 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $26,170.88 | 2019-2023 | Krystexxa |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $25,265.12 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,639.52 | 2019-2025 | Cyltezo, Ofev, Spevigo |
| E.R. Squibb & Sons, L.L.C. | $8,641.39 | 2019-2025 | Sotyktu, Orencia |
| Regeneron Healthcare Solutions, INC. | $6,836.38 | 2019 | |
| Alexion Pharmaceuticals, INC. | $1,637.74 | 2019-2025 | Strensiq |
| Pacira Therapeutics, INC. | $1,324.99 | 2019-2020 | |
| Glaxosmithkline, LLC. | $948.41 | 2019-2025 | Benlysta, Nucala |
| Sanofi-Aventis U.S. LLC | $546.25 | 2019-2024 | |
| Lilly USA, LLC | $447.10 | 2019-2024 | Taltz, Olumiant |
| Sandoz INC. | $427.69 | 2023-2025 | Hyrimoz, Jubbonti |
| Genentech USA, INC. | $328.59 | 2019-2025 | Gazyva, Actemra |
| Genentech, INC. | $251.77 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $223.55 | 2019 | |
| Organon LLC | $168.74 | 2023-2024 | Hadlima, Renflexis |
| Madrigal Pharmaceuticals | $112.45 | 2024 | Rezdiffra |
| Actelion Pharmaceuticals US, INC. | $90.36 | 2022-2025 | Opsumit, Uptravi |
| Scilex Pharmaceuticals INC. | $80.09 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.03 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $28.95 | 2024 | Arcalyst |
| Fresenius Kabi USA, LLC | $26.97 | 2025 | |
| Invivyd INC | $24.80 | 2025 | Pemgarda |
| Oxford Immunotec USA INC | $23.56 | 2020 | |
| Avion Pharmaceuticals | $21.08 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $20.63 | 2023 | Arcalyst |
| Celltrion USA INC. | $20.12 | 2023 | Yuflyma |
| Octapharma USA, INC. | $16.56 | 2024 | Octagam Immune Globulin (Human) |
| Daiichi Sankyo INC. | $14.97 | 2020 | |
| Bio Products Laboratory USA, INC. | $13.61 | 2021 | |
| Sobi, INC | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kostas Botsoglou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.